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The Gram-negative bacterial genus Elizabethkingia displays natural multiple 
antimicrobial resistance and is an emerging pathogen. One of the therapeutic agents still effective 
in the treatment of the Elizabethkingia are the fluoroquinolones (e.g. ciprofloxacin). Even though 
these drugs are effective, the emergence of target gene mutation-mediated resistance has been 
reported in E. anophelis and E. meningoseptica. Fluroquinolones target DNA biosynthesis by 
inactivating the DNA gyrase and topoisomerase IV which are produced by the gyrAB and parCE 
genes. I now intend to determine the mechanisms by which Elizabethkingia species become 
resistant to the fluoroquinolone ciprofloxacin. I hypothesized that any fluoroquinolone-resistant 
mutants would exhibit compromised growth, elevated MICs, and mutations in the quinolone 
resistance-determining regions (QRDRs) of gyrAB and/or parCE. First, I isolated 
fluoroquinolone-resistant mutants via single-step selection in media containing ciprofloxacin. 
Standard minimum inhibitory concentration assays were performed to compare suspected 
mutants to the parent. I also performed checkerboard assays to assess potential synergistic 
interactions between ciprofloxacin and the cell wall active antibiotic vancomycin. Changes in the 
growth of the mutants were compared to the parent strains using standard growth curves. Finally, 
I utilized cloning and Sanger sequencing to determine the sequences of the QRDRs in gyrAB and 
parCE in the confirmed fluoroquinolone-resistant mutants of E. ursingii. I determined that 
fluoroquinolone-resistant mutants showed MICs elevated up to 32-fold compared to their parent 
strains. Checkerboard assays showed that the drug interaction was not synergistic. I 
demonstrated slowed growth in almost all fluoroquinolone-resistant mutants compared to their 
respective parent strains, suggesting a growth fitness cost from the acquisition of 
fluoroquinolone resistance mutations. Sanger sequencing of the QRDRs in E. bruuniana did not 
reveal the presence of mutations common to other fluoroquinolone-resistant Gram-negative 
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bacteria. Further sequencing and experimentation are necessary to determine the mechanisms by 
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Elizabethkingia is a genus of Gram-negative bacteria of the family Flavobacteriaceae 
which was first delineated and defined in 2005 [1]. Elizabethkingia spp have been linked to cases 
of septicemia and neonatal meningitis since the earliest reported case in 1944 [2, 3]. It is an 
important emerging pathogen due to its intrinsic antibiotic resistance and ability to survive in 
unfriendly environments, such as those in hospitals and medical devices [4]. Elizabethkingia spp 
have caused clusters of outbreaks with high mortality rates in both community and healthcare 
settings, and readily infect and colonize hospital equipment such as ventilator tubing and faucet 
aerators [5].  
Elizabethkingia spp can be broadly divided into two groups. The first group, which is 
most clinically relevant, includes E. anophelis and E. meningoseptica. E. meningoseptica is the 
most widely-known species of Elizabethkingia, having been blamed for most of the severe cases 
and outbreaks in the last 75 years [6]. However, this began to change when E. anophelis was 
isolated from the gut bacteria of an anopheles mosquito in the Central African Republic in 2011. 
The first case report of an infection attributed to E. anophelis was published in 2013: meningitis 
in an 8 day old infant female in the Central African Republic [7]. Cerebrospinal fluid aspirate 
grew a Gram-negative rod identified as E. meningoseptica by mass-assisted laser desorption-
ionization time-of-flight mass spectroscopy (MALDI-TOF); however, the authors utilized 16S 
RNA sequencing techniques to demonstrate that this bacteria, as well as the preserved bacteria 
from a similar case in 2006, was actually E. anophelis. Later studies suggest that E. anophelis is 
actually the most prevalent infectious agent of the genus [8]. 
This case is a critical example of a known weakness of MALDI-TOF systems, which are 
common in clinical laboratory settings due to their efficiency. MALDI-TOF systems come from 
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the factory with a database of known bacteria which is used to compare to mass spectroscopy 
results [9]. The MALDI-TOF systems presently on the market do not have the full complement 
of Elizabethkingia species in their databases, so correct and specific identification of the bacteria 
in question is unlikely [10]. This has important implications for physicians because the efficacy 
of empirical antimicrobial therapy depends heavily on what bacteria is causing the infection in a 
patient. Adding to this difficulty is that Elizabethkingia species are not easily distinguishable by 
normal microbiological techniques, so more complex assays such as 16S RNA sequencing, 
whole genome sequencing, pulse-field gel electrophoresis, and/or in silico DNA hybridization 
are often used to establish a positive identity [1, 11]. 
The species of the Miricola group of Elizabethkingia include bruuniana, occulta, 
ursingii, and miricola. These four were originally considered one species, miricola, but were 
differentiated into species based on core genome comparative analysis [11]. The Miricola 
grouping is unofficial, but the four species are grouped together due to their genetic similarity. 
While E. anophelis and E. meningoseptica are the most relevant species from a clinical 
perspective, the other four species have all been implicated as the causative agent of infection in 
cases of septicemia, pneumonia, and cystic fibrosis around the world [11, 12].  
In many cases, Elizabethkingia infections have been treated with vancomycin because in 
early reports, Elizabethkingia infection showed susceptibility in vivo to vancomycin. However, 
more recent studies have presented evidence that the in vitro efficacy of vancomycin is 
diminished, and newer strains show heightened resistance [13]. In many strains, however, there 
is still susceptibility to other antibiotics, such as ciprofloxacin, which has shown varying levels 
of effectiveness over other antibiotics, such as rifampin and piperacillin/tazobactam [14]. 
Ciprofloxacin is a heterocyclic, fat-soluble antibiotic of the fluoroquinolone class which 
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indirectly inhibits DNA synthesis. Ciprofloxacin is a derivative of the first quinolone antibiotic, 
nalidixic acid, which was first isolated in 1962 as a byproduct of the synthesis of chloroquines, a 
class of antimalarial drugs [15]. Nalidixic acid was mostly used for urinary tract infections until 
further research led to a second generation of quinolones. The substitution of a fluorine at C6 and 
the addition of a large ring substituent improved the pharmacokinetics and therapeutic index of 
the drug, and ciprofloxacin is currently used to treat a variety of Gram-negative bacterial 
infections [16, 17]. 
Ciprofloxacin’s specific targets are the enzymes gyrase and topoisomerase IV. Both are 
type II topoisomerases which break phosphodiester bonds in the DNA strand and bind covalently 
to the strands to aid in winding and unwinding of the bacterial genome [18]. Both enzymes use 
energy from ATP to break DNA phosphodiester bonds using catalytic divalent metallic ions, and 
a tyrosine residue in the active site which binds covalently to the DNA. The two enzymes have 
different functions. Gyrase works with other topoisomerases (including the ω protein, a type I 
topoisomerase) and is responsible for controlling DNA supercoiling, which must be strictly 
controlled during DNA replication and transcription [19]. Topoisomerase IV is responsible for 
untangling the DNA strands which may become knotted during normal cellular function in a 
process known as decatenation [20]. Gyrase and topoisomerase IV are structural homologues 
with a heterotetrameric structure. Each protein has two subunits, A and B. Therefore, the 
subunits of Gyrase are written as GyrA and GyrB [21]. In Gram-negative topoisomerases, the 
proteins are abbreviated as ParC and ParE. In both cases, the B subunit is responsible for ATP 
binding and hydrolysis [19], while the A subunit defines the specificity of the enzyme [22, 23]. 
Poor conservation of sequence between gyrase and topoisomerase means that only Gyrase can 
4 
 
affect supercoiling [19]. It is important to note that the active site of both gyrase and 
topoisomerase are identical in structure and sequence. 
In the normal course of action, gyrase and topoisomerase move along the genome and are 
activated whenever necessary for genome maintenance and DNA replication. However, because 
their job is to fragment and stabilize the genome, the genome is destabilized whenever the 
enzymes are present [19]. 
Ciprofloxacin, like all quinolones, binds noncovalently to a serine residue (Ser83) at the 
active site of both enzymes and an acidic residue four amino acids downstream, mediated by a 
divalent cation [21-23] Ciprofloxacin may target either gyrase or topoisomerase IV and the 
specificity is not related to Gram status [24].The fluoroquinolone chelates the calcium ion with 
its C3 and C4 keto acids, and the magnesium ion then forms a hydrogen bond with the amino 
acid residues [21]. Binding of drug to gyrase and the fragmented DNA strand reversibly locks 
the enzyme in place on the DNA strand and inhibits the catalytic activity of the enzyme by 
preventing re-ligation of the DNA molecule [25]. Tension on the genome causes more 
topoisomerase enzymes to be dispatched, and they are in turn locked into place on the enzyme. 
When any DNA-scanning enzyme complex (such as helicase, the leading enzyme in a replication 
fork) collides with the inactivated type II topoisomerase, the genome is fragmented, and the cell 
is unable to repair this damage due to the inability to replicate the fragmented genome [26].  
Fluoroquinolones have a high therapeutic index because they are only effective against 
bacterial type II topoisomerases, and not human type II topoisomerases. This is because the 
human enzymes are not homotetramers but instead homodimers, with A and B subunits fused 
into a single protein. In addition, human type II topoisomerases lack the serine and acidic 
residues present in bacterial type II topoisomerases, preventing fluoroquinolones from chelating 
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to the enzyme [27]. While fluoroquinolones do not inhibit DNA synthesis in humans, they have 
been associated with CNS effects such as seizures, and they inhibit the CYP1A2 enzyme 
pathway [28]. 
Fluoroquinolone resistance may result from three processes: mutations in the genes 
which encode fluoroquinolone targets, such as gyrAB and parCE [29, 30], horizontal transfer of 
genes conferring resistance phenotypes [26, 31], and genomic regulation of fluoroquinolone 
entry via downregulation of porin protein expression and upregulation of multi-drug efflux pump 
protein expression [32-34].  
While the cause of ciprofloxacin resistance in Gram-negative species is well-understood, 
there is only one article in the literature about the efficacy of fluoroquinolones against 
Elizabethkingia, and that paper deals only with E. anophelis and E. meningoseptica and uses 
clinical isolates and their associated case reports [35]. However, cases of infection and disease 
caused by every known species of Elizabethkingia have been reported [12, 35] Furthermore, Lin 
et al., (2018) acknowledge that a handful of their clinical isolates were E. bruuniana but 
excluded these isolates from their experiments. Lin et al., (2018) identified 44 isolates of E. 
anophelis and meningoseptica resistant to levofloxacin and sequenced the genes encoding GyrA, 
GyrB, ParC, and ParE. They found mutations in the Ser83 position of GyrA (Ser83Ile and 
Ser83Arg), Ser95 (Ser95Pro), Lys102 (Lys102Gln); and in GyrB at positions 425 (Ile425Lys), 
452 (Arg452Ser), and 470 (Glu470Asp). No mutations in topoisomerase IV were observed in the 
fluoroquinolone-resistant strains examined [35]. 
In this study, I sought to characterize ciprofloxacin-resistant mutant strains of the 
Miricola group. In particular, I sought to characterize the effects that fluoroquinolone resistance 
mutations had on the fitness and antimicrobial resistance profiles of resistant strains. I also 
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attempted to find whether the mutations conferring fluoroquinolone resistance were similar to 
those in E. anophelis and E. meningoseptica. It has been demonstrated in other species that the 
mutations typically responsible for fluoroquinolone resistance also negatively affect bacterial 
growth and fitness [36]. I therefore sought to determine these effects. I hypothesized that a 
common mechanism of ciprofloxacin resistance, mutations in one or more of the genes encoding 
the GyrAB and ParCE proteins, would be the associated with resistance in the Miricola group, as 
is the case in E. anophelis and E. meningoseptica [35]. Furthermore, I hypothesized that the 





MATERIALS AND METHODS 
Mutant Isolation 
Four bacterial strains were used in this study: E. ursingii G4122T [37], E. miricola 
G4071T [38], E. bruuniana ATCC33958T [39], and E. occulta G4070T [38].  
Each strain was revived from freezer stock in 20% glycerol at -80°C on heart infusion 
agar (HIA) (Remel, San Diego, CA, USA) supplemented with defibrinated rabbit blood 
(Hemostat Laboratories, Dixon, CA, USA) and grown overnight at 37°C. Colonies were taken 
from this plate and incubated overnight at 37°C with shaking in 3 mL Mueller-Hinton Broth 
(MHB) (Beckton Dickinson and Company, Cockeysville, MD, USA).  
To isolate ciprofloxacin-resistant mutants, culture plates were prepared with Mueller-
Hinton Broth powder, granulated agar powder (Beckton Dickinson and Company, Cockeysville, 
MD, USA), and ciprofloxacin HCl (Sigma Aldrich, St. Louis, MO, USA) to create a variety of 
ciprofloxacin concentrations, ranging from 0.25 mg/L to 2 mg/L (final concentration). This was 
necessary in case inoculated plates did not produce any colonies after inoculation. The plates 
were inoculated using a spread-plating technique from the overnight MHB culture tubes and 
incubated for up to 48 h at 37℃. Any colonies which did grow on ciprofloxacin-containing 
media were suspected to be mutants. Suspected mutants were arbitrarily named “[Parent strain]-
CRS#,” e.g. G4122-CRS5. After naming, the mutant colonies were streaked onto drug-free 
MHA plates and incubated at 37℃ for 24-48 h before re-streaking on fresh media. This was 
repeated three times for three total drug-free plates per suspected ciprofloxacin-resistant mutant 
strain (“passages”).  
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Minimum growth-inhibitory concentration determination 
Mutant strains were tested for phenotypic confirmation of mutation by broth 
microdilution MIC assays to CLSA standards. Five mg/mL ciprofloxacin HCl was added to 
MHB to a concentration of 64 mg/L. MHB was placed in the wells of a 96 well plate. and the 
antibiotic was serially diluted across the plate using two-fold dilutions, so that ciprofloxacin 
concentrations tested ranged from 32 mg/L (25) to 0.0625 mg/L (2-4), with a positive control 
column (left-most column) containing no drug, and a negative control row containing no 
bacteria. One hundred μL of overnight culture in MHB at OD600nm = 0.010 ± 0.002 was added to 
each well, excluding the bacteria-free negative control rows. The plates were incubated at 37℃ 
for 24-48 h and examined visually to determine MIC.   
Synergy (checkerboard) assays 
Mutant strains of E. bruuniana were tested using a checkerboard assay to determine 
whether a synergistic interaction between ciprofloxacin and vancomycin was observed in the 
mutant strains. Plates were set up similar to the MIC assays above, and vancomycin (Sigma 
Aldrich, St. Louis, MO, USA) (starting concentration 128 mg/L) was then serially diluted 
vertically down the plate, forming a final concentration range from 32 mg/L to 0.5 mg/L, with 
the bottom row containing no vancomycin. Each well was then inoculated with 100 μL culture as 
described above and incubated at 37℃ for 24-48 h and examined visually to determine MIC and 
FIC. The fractional inhibitory concentration index (FICI) was calculated as the sum of the ratios 
of each drug’s FIC to its MIC, and standard conventions for breakpoints were followed (FICI < 
0.5 synergistic, 0.5 < FICI < 1.0 additive, 1.0 < FICI < 2.0 indifferent, FICI > 2.0 antagonistic).  
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Growth Curves  
To determine the growth characteristics of verified ciprofloxacin-resistant mutants, 
overnight cultures of the mutant strains were grown in MHB at 37℃ with shaking, alongside the 
parent strains as a control. The cultures were diluted to OD600nm = 0.010 ± 0.002 and 25 mL of 
culture were transferred to sterile 50 mL beveled Erlenmeyer flasks. The cultures were then 
grown at 37℃ with shaking at 200 RPM. OD600nm readings were taken hourly for eight hours, 
then at 16 h and 24 h. At the end of the 24 h period, the cultures were Gram stained to check for 
contamination and the bacteria were again challenged with ciprofloxacin as necessary. Because 
ciprofloxacin resistance is typically associated with decreased fitness, any strain which exhibited 
growth equivalent to or more vigorous than the parent strain in a 24 h growth curve was again 
challenged with ciprofloxacin. Ten μL of culture was withdrawn from the 50 mL growth flask 
and added to 3 mL MHB containing a concentration of ciprofloxacin equivalent to the mean of 
the parent and mutant’s MICs. For example, G4122-CRS1 exhibited elevated growth and an 
MIC of 4 mg/L compared to G4122-P, which exhibited an MIC of 0.5 mg/L. If bacteria grew, 
the strain retained its resistance, and if there was no growth after 48 h, the strain was assumed to 
have reverted to the parent phenotype. 
Primer Design, Genomic DNA extractions, and PCR 
Publicly available FASTA files containing the whole genome sequences of parent strains 
ATCC33958T[40], G4122T [38], G4070T [41], and G4071T [38] were downloaded and annotated 
using the RAST database [42-44]. The sequences of the genes for the A and B subunits of gyrase 
(GyrA and GyrB), and the C and E subunits of topoisomerase IV (ParC and ParE) were 
downloaded along with 500-750 base pairs on either side of the gene.  
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Sequencing primers for the QRDR regions were designed using NCBI’s PrimerBlast tool 
and optimized for melting temperature. Sequencing primers were designed to encompass all 
known Elizabethkingia QRDR mutations reported by Lin et al [35] with ample margin on each 
side of the genome to account for inaccuracies inherent to Sanger sequencing. The primer 
sequences and their Tm values are listed in appendix B. Primers were received from Integrated 
DNA Technologies (Coralville, IA, USA) in lyophilized tubes and reconstituted to 100μM 
before dilution to 10μM with ultrapure H2O. 
Chromosomal DNA of the parent strains were extracted using QIAGEN Genomic-tips 
(QIAGEN, Hilden, DE) according to manufacturer’s protocol and nanodropped. Genomes of the 
mutant strains were prepared via phenol:chloroform:isoamyl alcohol extraction [45] and 
dissolved in ultra-pure water. Samples of genomic DNA were assessed for purity and yield using 
a nanodrop spectrophotometer. 
PCR reactions were prepared so that each 200 μL tube contained 25 μL of OneTaq Hot 
Start Quick-Load 2x Master Mix with GC Buffer (New England Biosciences, Boston, MA, 
USA), 23 μL ultra-pure water, 1μL each of forward and reverse primers, diluted to 10 μM in 
Ultra-pure water, and 1 μL of genomic DNA. PCR protocols were developed to be specific to the 
Tm of each primer. PCR protocols used are listed in appendix D. 
Following amplification, the contents of the reaction tubes were electrophoresed through 
agarose gel. All gels used were 100 mL, 1% agarose with 1.5 μL of 10 mg/mL ethidium bromide 
(final concentration 0.15 mg/L), and all electrophoresis was carried out at constant 120V for 20 
minutes. Gel images were captured with a Bio-Rad Gel Doc XR+ imager and Image Lab 4.1 
software. Gel bands were excised using a razor blade and DNA was purified using New England 
Biosciences Gel Purification Kit #T1020 per manufacturer’s protocol, and DNA was eluted in 
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ultra-pure water and stored at 4℃. Samples of the purified amplicons were assessed for purity 
and yield using a nanodrop spectrophotometer. In some cases, the PCR product was merely 
sampled for successful amplification and the remainder was purified using New England 
Biosciences PCR Cleanup Kit #T1030 per manufacturer’s protocol to prevent product loss.  
Sequencing primers were diluted to 5 μM and purified DNA was submitted at no less 
than 5 ng/μL for sequencing, which was carried out using an ABI sequencer by the staff of the 






Mutation frequency, MICs, and synergy 
Colonies appeared on drug-containing plates at a rate of 10-8 for all four strains (Table 1). 
Analysis of ciprofloxacin MICs revealed that in all cases, the suspected fluoroquinolone-resistant 
mutants appeared to have increased fluoroquinolone resistance compared to respective parent 
strains (Table 1). In all cases, checkerboard assay results determined that for all E. bruuniana 
mutants, the drug combination of vancomycin and ciprofloxacin had an indifferent effect, 
meaning that the combination performed no better than each drug individually (Table 2).  
Table 1: Selection Concentration, Mutation Frequency, and Ciprofloxacin MICs 







G4122-P ursingii  1.5 3.13 X 10-8 0.5 
G4122-CRS1 ursingii  4 
G4122-CRS2 ursingii 2 
G4122-CRS3 ursingii 8 
G4122-CRS4 ursingii 4 
G4122-CRS5 ursingii 1 
G4071-P miricola 2 9.04 X 10-8 1 
G4071-CRS1 miricola  4 
G4071-CRS2 miricola 8 
G4071-CRS3 miricola 8 
ATCC33958-P bruuniana  1 9.38 X 10-8 0.5 
ATCC33958-CRS1 bruuniana   2 
ATCC33958-CRS2 bruuniana  2 
ATCC33958-CRS3 bruuniana  8 
ATCC33958-CRS4 bruuniana  8 
G4070-P occulta  1.5 4.77 X 10-8 0.25 
G4070-CRS1 occulta  16 
G4070-CRS2 occulta 2 
G4070-CRS3 occulta 4 



















1.25 0.75 12 2 1.3125 Indifferent 
ATCC-
CRS1 
9.3 3.3 18.7 6.7 1.083 Indifferent 
ATCC-
CRS2 
9.3 6.7 13.3 4 1.167 Indifferent 
ATCC-
CRS3 
5.7 5.7 10.7 5.3 1.5 Indifferent 
ATCC-
CRS4 






Standard growth curves showed that, in general, mutant strains grew slower than their 
parent strains. However, some strains (E. ursingii G4122-CRS1 and G4122-CRS2, E. ursingii 
ATCC33958-CRS2) grew as well as or better than the parent. G4122-CRS1 and G4122-CRS2 










































































E. miricola G4071 Growth Curves
G4071-P CRS1 CRS2 CRS3
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QRDR translated sequences 
Sequences of the sense and antisense strands of the QRDRs of gyrA, gyrB, parC, and 
parE revealed no mutations in the QRDRs when compared to known wild-type sequences. In all 
GyrA forward sequences, at least two substitutions are visible at the beginning of the sequence, 
but comparing the forward and reverse sequences revealed nucleotide mismatches in these 
positions of the forward strand. The protein sequences (translated from the raw sequences) of all 




Like other species of Elizabethkingia, the Miricola group readily acquires resistance to 
ciprofloxacin with mutation frequencies of 10-8 mutants (Table 1) and shows elevated MICs 
(Table 1) well beyond the maximum serum concentration of a maximum oral dose of 
ciprofloxacin HCl [28], making ciprofloxacin ineffective as a therapeutic agent in cases of 
infection with organisms expressing similar levels of ciprofloxacin resistance. Synergy assays 
with ciprofloxacin and vancomycin in fluoroquinolone-resistant E. bruuniana ATCC33958 
(Table 2) indicate an indifferent relationship between the two drugs and suggest that the two 
drugs are eliminated from the cell by the same system, which functions comparably in the parent 
and fluoroquinolone-resistant strains as shown by their comparable vancomycin MICs. 
Examination of the growth of fluoroquinolone-resistant mutants revealed that growth was 
often compromised, but not consistently within or across species. E. occulta G4070 
fluoroquinolone-resistant strains demonstrated slower growth than the parent by 8 and 16 h, but 
by 24 h had caught up to the parent. This is not the case for E. ursingii G4122, where three of the 
five strains show completely compromised growth and see their OD600nm decline from 16 to 24 h. 
Curiously, G4122-CRS1 and -CRS2 both out-grew the parent, indicating that some sort of 
compensatory mutation might have been acquired which negates the effect on growth that the 
mutations causing ciprofloxacin resistance might have caused. The growth curves of E. 
bruuniana ATCC33958 are also unique, as they indicate that ATCC33958-CRS3 and 
ATCC33958-CRS4 show significantly compromised growth when compared to the parent and 
ATCC33958-CRS1 and ATCC33958-CRS2. E. miricola G4071 shows the most consistent 
growth of the four species tested, but the range of values between the four strains suggests that 
none of the three fluoroquinolone-resistant strains has the same set of mutationsWhile 
compromised growth is consistent with gyrase or topoisomerase IV mutations, the causal 
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relationship is not elucidated by these data. In fact, the ability of some strains to keep pace with 
or exceed the parent strain’s growth would indicate that whatever mutations confer 
fluoroquinolone-resistance are not in the QRDRs of gyrase or topoisomerase IV. In fact, it is 
reasonable to assume that in all Elizabethkingia strains tested, the variety of growth profiles 
could be due to a variety of mutations. Furthermore, the difference in growth being based on the 
nature of the mutation suggests that various mutations have different energetic costs to the cell 
and thus compromise growth by requiring excess energy which could be used for replication.   
However, the growth curves may be flawed for a number of reasons. First, measurements 
of OD600nm were used as a stand-in for CFUs/mL. A more accurate way of determining 
CFUs/mL would have been to serially dilute samples from the flasks and inoculate the samples 
onto agar plates. Optical density measurements were used because they were simpler and more 
economical. However, optical density measurements assume that the culture’s optimal 
absorbance remains at 600nm for the duration of the assay and assumes that no changes in 
phenotype (such as a stress phenotype, where the cells elongate into filaments) affect the 
absorbance. Furthermore, a spectrophotometer cannot tell between viable cells, apoptotic cells, 
or cell debris. Therefore, it is likely that CFUs/mL were likely lower than a related OD600nm 
value would suggest. Second, no replicates of the growth curve experiments were performed due 
to time constraints. Replicates might have painted a clearer picture about the nature of the growth 
of all fluoroquinolone-resistant strains.  
The validity of OD600nm compared to CFUs/mL notwithstanding, it is clear that some 
form of mutation has occurred in the majority of fluoroquinolone-resistant strains which has 
imparted that drug resistance and simultaneously affected cell growth. One likely candidate for 
mutation would be the QRDRs of gyrase and topoisomerase IV. However, the complete absence 
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of mutations within the QRDR sequences of E. bruuniana rules this out, contrary to my 
hypothesis. If gyrase and topoisomerase are unaffected in fluoroquinolone-resistant mutants, then 
ciprofloxacin likely still has its standard effect on the enzymes: the drug chelates to the 83Ser 
residue, freezing the enzyme in place on the DNA strand. However, the increase in MIC for all 
strains would suggest that resistance is not due to mutations in the target genes.  
An alternative mechanism for fluoroquinolone resistance is based on drug influx and 
efflux. Fluoroquinolones enter Gram-negative cells through porin proteins via diffusion and may 
be forced back out by active transport using one or more multi-drug efflux pumps [32]. 
Elizabethkingia are thought to have several classes of drug efflux pumps based on putative 
RAST annotation, but this has not been confirmed in vitro [33]. Regulation of the expression of 
such proteins could explain the increased drug resistance. One final mechanism, though far-
fetched, may be possible: chemical modification of ciprofloxacin. Limited evidence suggests that 
fluoroquinolone-degrading enzymes exist in nature[46]. In silico modeling of many bacterial 
proteins has suggested that mutations or modifications in some oxidoreductases and 
decarboxylases would cause pyrolysis or decarboxylation of fluoroquinolones, a topic of interest 
in sewage treatment as fluoroquinolone metabolites form micropollutants in sewage[47]. It is 
possible that Elizabethkingia chemically modifies ciprofloxacin to reduce toxicity using a 
nonspecific oxidoreductase or decarboxylation pathway, but further testing is needed to 
determine if this is the case.  
Future directions of this study should be divided into four phases. First, the QRDRs of E. 
occulta, E ursingii, and E. miricola should be sequenced to find gyrase and/or topoisomerase IV 
mutations. It was my intent to do this work for E. ursingii due to its unusual growth curves, but 
due to time constraints and factors beyond my control I was unable to complete this task. 
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Second, quantitative RT-PCR could be used to determine how Elizabethkingia upregulates and 
downregulates porins and efflux pumps under ciprofloxacin challenge. Third, sequencing the full 
lengths of gyrAB and parCE, and whole genome sequencing could be used to identify mutations 
outside the QRDRs which may contribute to ciprofloxacin resistance. Finally, an investigation of 




Appendix A: Strains used 





ATCC33958T bruuniana Contaminated commercial enzyme 

















bruuniana Selected from ATCC33958T 1 This 
study 
G4071T miricola Tracheal exudate; Strasbourg, 
France; 1978 
N/A [38] 
G4071-CRS1 miricola Selected from G4071T 2 This 
study 
G4071-CRS2 miricola Selected from G4071T 2 This 
study 
G4071-CRS3 miricola Selected from G4071T 2 This 
study 
G4122T ursingii Soil; Odense, Denmark; 1964 N/A [37] 
G4122-CRS1 ursingii Selected from G4122T 1.5 This 
study 
G4122-CRS2 ursingii Selected from G4122T 1.5 This 
study 
G4122-CRS3 ursingii Selected from G4122T 1.5 This 
study 
G4122-CRS4 ursingii Selected from G4122T 1.5 This 
study 
G4122-CRS5 ursingii Selected from G4122T 1.5 This 
study 
G4070T occulta Sputum; Melbourne, Australia; 
1977 
N/A [38] 
G4070-CRS1 occulta Selected from G4070T 1.5 This 
study 
G4070-CRS2 occulta Selected from G4070T 1.5 This 
study 
G4070-CRS3 occulta Selected from G4070T 1.5 This 
study 





Appendix B: Primers 
All amplification and sequencing reactions were performed using the same set of primers. 





ATCC GyrA F 65-120 195-360 GAGCGTTACCGGACGTAAGA 570 60 
ATCC GyrA R TACCTCCGGTTGGGAAGTCT 60 
ATCC GyrB F 420-470 1260-1410 GACAGGCAGCTAAGAAGGCT 322 60 
ATCC GyrB R AGGTTAAGTGCCTTGCTGTCT 60 
ATCC ParC F 75-120 225-360 GACTGAAACCCGTACAGCGA 359 60 
ATCC ParC R TGCCAGAAGCAAAGGGAACT 60 
ATCC ParE F 420-470 1260-1410 GAGGGAGATTCCGCATCAGG 486 60 
ATCC ParE R CAAGTCCCTTGAATCGCGTG 60 
 
Appendix C: PCR protocol 
All PCR reactions were performed under the following conditions:  
1. Melt at 94℃ for 4:30 
2. Melt at 94℃ for 0:30 
3. Anneal at 55℃ for 0:30 
4. Extend at 68℃ for 5:00 
5. Repeat steps 2-4 30 times 
6. Final extension at 68℃ for 5:00 (total of 10:00) 




Appendix D: Sequences of GyrA, GyrB, ParC, ParE from E. bruuniana ATCC33958 
fluoroquinolone-resistant strains 
 
E. bruuniana ATCC33958-CRS1 (from top to bottom) GyrA, GyrB, ParC, ParE 
 




E. bruuniana ATCC33958-CRS3 (from top to bottom) GyrA, GyrB, ParC, ParE  
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